Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
8.74
-0.45 (-4.90%)
At close: Oct 30, 2026, 4:00 PM EDT
8.79
+0.05 (0.57%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Alpha Cognition Revenue
Alpha Cognition had revenue of $6.09M in the quarter ending June 30, 2026, with 267.56% growth. This brings the company's total for the last twelve months to $15.26M, up 232.74% year-over-year. In the year 2025, Alpha Cognition had annual revenue of $10.22M. That makes Alpha Cognition the 35,324th largest company in the world by revenue and 4,655th in the United States.
Revenue (ttm)
$15.26M
Revenue Growth
+232.74%
P/S Ratio
12.47
Revenue / Employee
$214,940
Employees
71
Market Cap
190.34M
Revenue by Geography
- United States 6.79M 66.5%
- China 3.43M 33.5%
Fiscal year ended Dec 31, 2025 See the full Alpha Cognition breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.22M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 74.00M |
| Precision BioSciences | 45.06M |
| Zentalis Pharmaceuticals | 26.87M |
| ProQR Therapeutics | 21.05M |
| Whitehawk Therapeutics | 7.15M |
| Upstream Bio | 3.16M |
| Cartesian Therapeutics | 1.48M |
| Palisade Bio | 500.00K |
ACOG News
- 18 days ago - Alpha Cognition announces publication of US patent application for ZUNVEYL - TheFly
- 18 days ago - Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL® - Business Wire
- 25 days ago - Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress - Business Wire
- 4 weeks ago - Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Alpha Cognition announces CONVERGE RWE on ZUNVEYL - TheFly
- 4 weeks ago - Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care - Business Wire
- 5 weeks ago - Alpha Cognition management to meet virtually with B. Riley - TheFly
- 2 months ago - Alpha Cognition initiated with a Buy at B. Riley - TheFly